Glycostem Therapeutics B.V.

[Available On-Demand]
We are focused on the development of stem cell-derived Natural Killer cells (NK cells) as a medicinal asset in the fight against cancer. NK cells are the new star in the domain of cellular immunotherapy, due to their tightly regulated “natural killing” of cancer cells; they play an important role in control and even cure of both solid and hematological malignancies, like acute myeloid leukemia (AML) and multiple myeloma (MM). We have a pipeline of 4 genetically modified NK cells; 3 CAR-NK and one TCR-NK.
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Netherlands
Year Founded:
2007
Main Therapeutic Focus:
Lead Product in Development:
oNKord
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
5 products
Speaker
photo
Chairman/CEO
Glycostem Therapeutics